Results 61 to 70 of about 115,309 (309)

BRCA1 regulates p53-dependent gene expression [PDF]

Proceedings of the National Academy of Sciences, 1998
Mutations in BRCA1 are present in 45% of families that segregate with susceptibility for breast cancer and in 80–90% of families with both breast and ovarian cancer. Here we report that BRCA1 stimulates artificial and genomic promoter constructs containing p53-responsive elements.
T, Ouchi, A N, Monteiro, A, August, S A, Aaronson, H, Hanafusa   +4 more
openaire   +2 more sources

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Expression of BRCA1 and BRCA2 Genes in Patients Undergoing Transrectal Prostate Biopsy

Revista Brasileira de Cancerologia
Introduction: Prostate cancer (PCa) is the second most common type of cancer among the male population. Men carrying mutations in the BRCA1 and BRCA2 genes are known to have a greater risk of developing PCa.
Eduardo Maciel Narvaes, Alyna Araújo e Marcondes, Roberto de Andrade Garcia Filho, Paulo Gabriel da Silva Mota, Patricia de Lima Lemos, Claudinéia de Araújo   +5 more
doaj   +1 more source

Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences

Hereditary Cancer in Clinical Practice, 2019
Background Genetic testing for hereditary cancer syndromes has been revolutionized by next-generation sequencing, which allows for simultaneous review of numerous genes.
Kristin E. Clift, Sarah K. Macklin, Stephanie L. Hines   +2 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer

BMC Medical Genetics, 2011
Background Germline mutations in either of the two tumor-suppressor genes, BRCA1 and BRCA2, account for a significant proportion of hereditary breast and ovarian cancer cases.
Llombart Pilar, Garcia Ana, Llopis Francisco, Rubio Luis, Fernandez-Serra Antonio, Romero Ignacio, Garcia-Casado Zaida, Lopez-Guerrero Jose A   +7 more
doaj   +1 more source

A theory for the tissue specificity of BRCA1/2 related and other hereditary cancers [PDF]

, 2010
Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast and ovarian cancer that are so high and seem so selective that many mutation carriers choose to have prophylactic surgery. There has been much conjecture to explain such apparently
Bernard Friedenson
core   +1 more source

An introspective update on the influence of miRNAs in breast carcinoma and neuroblastoma chemoresistance [PDF]

, 2014
Chemoresistance to conventional cytotoxic drugsmay occur in any type of cancer and this can either be inherent or develop through time. Studies have linked this acquired resistance to the abnormal expression of microRNAs (miRNAs) that normally silence ...
Carta, Alessia, Chetcuti, Rachel, Ayers, Duncan   +2 more
core   +2 more sources

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa

BMC Cancer, 2022
Background Elucidation of specific and recurrent/founder pathogenic variants (PVs) in BRCA (BRCA1 and BRCA2) genes can make the genetic testing, for breast cancer (BC) and/or ovarian cancer (OC), affordable for developing nations.
Oubaida ElBiad, Abdelilah Laraqui, Fatima El Boukhrissi, Chaimaa Mounjid, Maryame Lamsisi, Tahar Bajjou, Hicham Elannaz, Amine Idriss Lahlou, Jaouad Kouach, Khadija Benchekroune, Mohammed Oukabli, Hafsa Chahdi, Moulay Mustapha Ennaji, Rachid Tanz, Yassir Sbitti, Mohammed Ichou, Khalid Ennibi, Bouabid Badaoui, Yassine Sekhsokh   +18 more
doaj   +1 more source